• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks
    life science investing

    Medication Errors Affect 1.2 Million US Hospitalizations a Year, Study Shows

    Charlotte McLeod
    Dec. 10, 2012 12:28PM PST
    Life Science Investing News

    Peer-reviewed journal American Health & Drug Benefits reported that its new study indicates that medication errors, specifically those related to injectable medications, affect 1.2 million US-based hospitalizations a year. These errors, also known as preventable adverse drug events, result in an average of $600,000 per year in extra costs per hospital.

    Peer-reviewed journal American Health & Drug Benefits reported that its new study indicates that medication errors, specifically those related to injectable medications, affect 1.2 million US-based hospitalizations a year. These errors, also known as preventable adverse drug events, result in an average of $600,000 per year in extra costs per hospital.

    As quoted in the market news:

    Based on this medication-level analysis of reported harmful errors and the frequency of inpatient administrations with actuarial projections, we estimate that preventable ADEs associated with injectable medications impact 1.2 million hospitalizations annually. Using a matched cohort analysis of healthcare claims as a basis for evaluating incremental costs, we estimate that inpatient preventable ADEs associated with injectable medications increase the annual US payer costs by $2.7 billion to $5.1 billion, averaging $600,000 in extra costs per hospital.

    Click here to read the full American Health & Drug Benefits report.

    life science investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Merck Announces First-Quarter 2023 Financial Results

    Merck Announces First-Quarter 2023 Financial Results

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing News Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×